Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.
Amita Patnaik(South Texas Accelerated Research Therapeutics), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kyriakos P. Papadopoulos(Texas Oncology), C. Jordán Peréz(South Texas Accelerated Research Therapeutics), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Kevin Gergich(Merck & Co., Inc., Rahway, NJ, USA (United States)), Drew Rasco(Texas Oncology), Cong Chen(Fujian University of Traditional Chinese Medicine), Lon Smith(Texas Oncology), Ronald Drengler(South Texas Accelerated Research Therapeutics), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Muralidhar Beeram(Urology San Antonio)
Cited by 82
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k